What happened
Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy
SourceCell PresspublicationBiotech
Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy
Publication signal: Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy
Factual summary
Why it matters
Recent source-backed research output for AISci Stage A browsing.
SourceCell PressLimitations
AISci rank score does not assess scientific quality or citation impact.
SourceCell PressLinked output
Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapypaperPeople
No reviewed person relationship is attached to this event.
Organizations
No reviewed organization relationship is attached to this event.
Topics
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy
Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy
Diagnostics and Biomarkers
Controlled AISci Stage A topic for Diagnostics and Biomarkers.
Timeline
- publicationApplication of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy